bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version exsight capital  home   exsight capital   exsight capital home team founding story impact investing contact home team founding story impact investing contact exsight capital is a venture capital firm specializing in earlystage impact investments in innovative ophthalmic diagnostic and treatment solutions  the firm consists of  accomplished retinal surgeons and a team of investment professionals that have partnered to address the need for funding early stage ophthalmic focused companies  the firm seeks investments in biotechnology medical devices pharmaceuticals and software solutions in ophthalmology  news exsight invests in trefoil therapeutics exsight participated in an investment in trefoil therapeutics inc an early stage biopharmaceutical company focused on developing a regenerative approach to corneal endothelial dystrophies and other diseases the  million round was led by hatteras venture partners with additional participation from other notable investorsexsight’s dedication to improving visual outcomes is evident in trefoil’s commitment to patients with an unmet medical need patients with corneal endothelial deficiencies including bullous keratopathy and fuchs’ dystrophy experience pain and loss of vision the current treatment paradigm requires a risky and invasive corneal transplant that is prone to failure trefoil’s tthx a novel engineered derivative of fibroblast growth factor efgf regenerates corneal endothelial cells enabling them to resume regular formation thereby restoring visual acuity delivered by intracameral injection the procedure presents significantly less risk than transplant trefoil’s innovations promise to improve patients’ lives with a more efficacious treatment and significantly lower risk minimally invasive procedure read here for the companys announcement   exsight invests in vision restoration allergan acquires gene therapy company retrosense therapeutics retrosense therapeutics raises  million in an oversubscribed series b financing to advance clinical development of lead product rst00 for retinitis pigmentosapatient recruitment underway for phase iii clinical studynovember  0ann arbor michretrosense therapeutics  a privatelyheld clinicalstage biopharmaceutical company today announced that it has secured  million in a series b financing to further investigate the use of gene therapy and optogenetics to restore vision the investment syndicate includes existing investors including bluewater angels and new investors rbv capital exsight capital and santen pharmaceutical co ltdsee  business wire for more allergan plc nyse agn a leading global pharmaceutical company and retrosense therapeutics llc  a private clinicalstage biotechnology company focused on novel gene therapy approaches to restore vision in patients suffering from blindness today announced that allergan has acquired substantially all of the assets of retrosense in an allcash transaction under the terms of the transaction allergan has paid retrosense a 0 million upfront payment and has agreed to potential regulatory and commercialization milestone payments related to its lead development program rst00 a novel gene therapy for the potential treatment of retinitis pigmentosa rpread here for the full press release and here for allergans presentation    exsight capital management llc                    privacy policy                    terms and conditions          disclaimer        ✕ about — loop therapeutics an ophthalmic pharmaceutical company loop therapeutics is currently undergoing preclinical work towards the development of different products that will treat diseases in the front and the back of the eyeloop therapeutics has licensed the development of one of its candidates for ent applications to spiral therapeutics a hearing loss pharmaceutical companyloop therapeutics is looking for partnerships to continue to develop its candidates for indications in other therapeutic areasif you are interested in a potential collaboration do not hesitate to contact us  contact us → loop therapeutics an ophthalmic pharmaceutical company  spun out in 04 from the spanish pharmaceutical company salvat loop therapeutics is a pharmaceutical company focused on developing firstinclass products for the prevention of apoptosis  contact us →   trefoil therapeutics inc  relationship science news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink trefoil therapeutics inc overview executives  employees board of directors paths recent transactions investors trefoil therapeutics inc overview date founded 03 headquarters 4 almondwood way san diego ca 30 industries pharmaceuticals holding companies company description trefoil therapeutics inc operates as development stage company which focuses on the application of novel engineered fgf compounds the firm develops applications for the efgfs include regenerative therapies that may address a broad range of ischemic disease including coronary heart disease diabetic ulcers and peripheral artery disease the company was founded by ralph bradshaw ken thomas and michael blaber in 03 and is headquartered in san diego ca website httpwwwtrefoiltherapeuticscom executives  employees michael blaber cofounder david eveleth chief executive officer ralph a bradshaw chief scientific officer  director see our list of current and previous employees when you upgrade start my free trial ➤ see more board of directors christy l shaffer general partner at hatteras venture partners benjamin f mcgraw iii executive chairman  chief executive officer at theravida inc david eveleth chief executive officer at trefoil therapeutics inc derek yoon partner at aju ib investment us ralph a bradshaw chief scientific officer  director at trefoil therapeutics inc see our list of current and previous board members when you upgrade start my free trial ➤ see more paths to trefoil therapeutics inc trefoil therapeutics inc you connections via relationship science trefoil therapeutics inc sync your contacts to see how you can connect with trefoil therapeutics inc start my free trial ➤ see more recent transactions details hidden trefoil therapeutics inc raised money in a private placement transaction investors details hidden michael blaber cofounder at trefoil therapeutics inc details hidden exsight capital management llc exsight capital management llc is a private company headquartered in dover de that acts as an alternative investment manager details hidden correlation management llc correlation management manages a quantitativelybased venture capital fund that employs a proprietary algorithm to passively invest in venture capital deals led by other venture capital firms details hidden aju ib investment co ltd aju ib is a longterm investor focused on high technology korean companies with significant growth potentialaju ibs investment criteria include managements capability ethics and transparency potential market leadership or ability to control the market technological barriers to entry significant market size profitability and maturity they also take into consideration portfolio diversification youve reached your 0 free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ trefoil therapeutics trefoil therapeutics eyewire today  trefoil therapeutics development program with florida state university to focus on the treatment of corneal dystrophies home eyewiretv news events login username password home eyewiretv news events trefoil therapeutics development program with florida state university to focus on the treatment of corneal dystrophies source trefoil therapeutics tuesday march 4 0  partnerships trefoil therapeutics announced the signing of a license and research agreement with florida state university for the development of engineered fgf derivatives efgfs according to a company news release this agreement gives trefoil an exclusive license to the efgf patent estate for therapeutic and cosmetic uses this collaboration will advance the existing efgf technology developed by dr michael blaber professor at fsu and a cofounder of trefoil the efgf platform represents an innovative approach to the improvement of pharmacokinetic properties of fibroblast growth factors as drugs yielding novel fgfs these efgfs have demonstrated superior pharmacodynamic and pharmaceutical properties compared to the naturally occurring fgfs in animal models of tissue healing a lead compound for development for corneal regeneration has been selected tthx04 and trefoil is moving this compound towards an ind application corneal regeneration has been shown in in vitro rabbit models brent edington head of the office of commercialization at fsu noted that “this collaboration for the development of novel therapeutics demonstrates the strength of fsu’s research programs and the focus of scientists at fsu on research relevant to human benefit” “trefoil is delighted to be able to partner with the powerful research capabilities of fsu and the blaber laboratory for the further development of the efgf technology” said dr david eveleth phd ceo of trefoil the first therapeutic application focuses on eliminating the most common driver of corneal transplantation fuchs corneal dystrophy which can lead to severe visual loss for which there is currently no approved pharmaceutical therapy   “corneal dystrophies are a category of serious sight threatening conditions that have limited treatment options today aside from surgical intervention” william trattler md director of the center for excellence in eye care miami said in the news release “there is a significant need for therapeutic agents that can treat or slow the progression of this category of diseases and this innovative new class of drug may significantly expand our treatment options” the broad family of patents covering efgfs was also bolstered recently by the issuance of us patent  which describes additional fibroblast growth factor mutants with improved functional halflife and use methods  further over the last  months several other patents have been filed covering new aspects of efgf technology and strengthening the intellectual property protection for these novel therapeutics trefoil also announced the addition of two new members of its team schalon newton dm has been appointed chief business officer and will be responsible for business development partnering and strategy mr schalon was the head of business development at santen and spent more than 0 years at allergan including leading allergan’s japanese subsidiary  william stewart md will serve as a development consultant to trefoil leading the development of the clinical strategy and the initial clinical trial  dr stewart is an ophthalmologist and founder of prn a leading clinical ophthalmic contract research organization and pharmafarm which assists startups with unique innovative technology such as trefoil with their development process comments you must be logged in to leave a comment upcoming events   advanced refractive congress 0 oisasrs featured stories thursday july    fda approvalclearance product releases quantel medical quantel medical receives fda approval for easyret photocoagulator laser quantel medical announced that it has received approval from the fda for the easyret fully integrated nm yellow photocoagulator which is used to t… read the full story wednesday july    clinical trials earnings  financials amd ophthotech ophthotech expands focus with development for ophthalmic orphan diseases ophthotech announced that the company is pursuing a strategy to leverage its clinical experience and retina expertise to identify and develop therapie… read the full story monday july 4   product releases cenegermin eye drops for the treatment of neurotrophic keratitis receive european union approval dompe announced that the european commission has granted the marketing authorization of cenegermin eye drops for the treatment of moderate to severe n… read the full story friday july    dry eye medical studies tfos dews ii report published dry eye disease redefined the longawaited tear film  ocular surface society tfos dry eye workshop ii dews ii report was published on july   updating the defin… read the full story tuesday july    earnings  financials alcon latest novartis earnings show signs of a rebound at alcon as part of its second quarter earnings novartis reported that sales at its alcon unit accelerated in the second quarter novartis chief executive joe… read the full story news company news product news research meetings   events eyewiretv login acquisitions blindness clinical trials conferencesmeetings lawsuits earnings  financials fda approvalclearance glaucoma health care international approvals managementleadership medical studies miscellaneous optometry partnerships practice development product releases retina contact advertising about send a tip or event     bryn mawr communications llcall rights reserved